Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers

Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.

Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.